Access to Advanced Health Institute
- Company typePrivate
- Founded1993
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Access to Advanced Health Institute firmographics
Firmographics- Name
- Access to Advanced Health Institute
- Legal name
- Access to Advanced Health Institute
- Website
- https://aahi.org
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Access to Advanced Health Institute industry classification
Industry- Product category
- Vaccine Research and Development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Adjuvants & Formulation Systems (HLAIAEAI)
- akta.pro secondary industries
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Adult Vaccines (HLAIAEAB)
Keywords
Where Access to Advanced Health Institute is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
Access to Advanced Health Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Access to Advanced Health Institute product offering
Product offeringCore offering
AAHI is a nonprofit research institute that develops proprietary vaccine platform technologies, including the NanoAlum nanoparticle adjuvant formulation for tuberculosis and influenza vaccines and a temperature-stable, single-dose chikungunya RNA vaccine. Its products are engineered to be safer, more effective, and easier to manufacture and distribute in low-resource and endemic regions.
Product overview
Access to Advanced Health Institute (AAHI) is a vaccine research and development organization developing novel vaccine technologies and formulations. The organization's product portfolio includes NanoAlum, a nanoparticle adjuvant platform for improving immune responses against tuberculosis and influenza, and a chikungunya RNA vaccine utilizing temperature-stable, single-dose technology. These products aim to address vaccine accessibility challenges in low-resource and endemic regions through advanced formulation science and RNA platform technology.
Differentiator
Problem solved
Functional benefit
Products and services
- NanoAlum A novel nanoparticle adjuvant formulation designed to improve vaccine immune responses against tuberculosis and influenza, intended to be combined with immune-stimulating molecules such as 3M's 3M-052 to produce vaccines that are safer, more effective, and easier to manufacture in low-resource settings.
- Chikungunya RNA Vaccine A temperature-stable, single-dose chikungunya vaccine using RNA platform technology that generates a live-attenuated virus, designed for easier manufacturing and distribution to endemic regions and targeting improved accessibility and efficacy for poor and marginalized populations.
Quantifiable outcome
- Development of temperature-stable vaccines that can be manufactured with standard techniques and distributed to endemic regions
- +1 more outcomes
Companies that use Access to Advanced Health Institute
Customer profileSegments1 record
Ideal customer profiles2 records
Access to Advanced Health Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Access to Advanced Health Institute partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- 3Mcore3M is providing its immune-stimulating molecule 3M-052 for evaluation in combination with AAHI's NanoAlum nanoparticle adjuvant formulation. This collaboration aims to develop improved vaccines against tuberculosis and influenza that are safer, more effective, and easier to manufacture, particularly in low-resource areas.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Access to Advanced Health Institute competitors and assessment
Company assessmentDirect peers
- International Vaccine Institute: Seoul-based nonprofit international organization dedicated to vaccine R&D for developing countries, with focus on diseases of poverty. Directly comparable as a nonprofit vaccine R&D institute targeting neglected tropical diseases and LMIC deployment.
- Sabin Vaccine Institute: Nonprofit vaccine R&D organization advancing vaccines for neglected tropical and emerging infectious diseases. Highly comparable as a nonprofit peer developing vaccines specifically for low-resource settings with global health partners.
- PATH: Global health nonprofit that advances and delivers vaccines and other health technologies for LMICs. Comparable as a large nonprofit ecosystem player developing and deploying vaccines targeting similar endemic-region diseases.
- Texas Children's Hospital Center for Vaccine Development (Baylor): Academic nonprofit product development partnership focused on vaccines for hookworm, schistosomiasis and other neglected tropical diseases. Comparable nonprofit vaccine R&D model targeting diseases of poverty with global health deployment focus.
- Hilleman Laboratories: Singapore-based nonprofit vaccine R&D organization developing affordable vaccines for low- and middle-income countries. Comparable as a nonprofit focused on accessible, low-cost vaccine design for underserved populations.
Emerging players
- Novavax: Clinical-stage vaccine developer specializing in nanoparticle recombinant vaccine technology with Matrix-M adjuvant. Comparable at the technology level via shared nanoparticle-adjuvant approach, but operates as a commercial developer with broader infectious disease targets.
- Gennova Biopharmaceuticals: India-based biotech developing mRNA-based vaccines tailored for emerging markets and low-resource settings, including temperature-stable formulations. Comparable as an emerging player focused on accessible RNA vaccine technology for LMIC deployment.
Broad incumbents
- CureVac: Commercial biopharmaceutical company pioneering mRNA-based vaccines and therapeutics. Comparable at the RNA vaccine platform level, though CureVac operates with commercial scale and broader oncology/infectious disease ambitions.
- Moderna: Commercial mRNA vaccine leader with an infectious disease pipeline including influenza and emerging-disease programs. Comparable at the RNA vaccine platform layer, but operates at vastly greater commercial scale and capitalization.
Others
- Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding and coordinating development of vaccines against emerging infectious diseases. Comparable as a key funder/ecosystem participant relevant to AAHI's chikungunya and outbreak-pathogen vaccine development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Access to Advanced Health Institute social profiles
Digital presenceAccess to Advanced Health Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Access to Advanced Health Institute leadership team
Management profileNumber of profiles
Access to Advanced Health Institute funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Access to Advanced Health Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Access to Advanced Health Institute
What does Access to Advanced Health Institute do?
AAHI is a nonprofit research institute that develops proprietary vaccine platform technologies, including the NanoAlum nanoparticle adjuvant formulation for tuberculosis and influenza vaccines and a temperature-stable, single-dose chikungunya RNA vaccine. Its products are engineered to be safer, more effective, and easier to manufacture and distribute in low-resource and endemic regions.
Is Access to Advanced Health Institute a public or private company?
Access to Advanced Health Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Access to Advanced Health Institute founded?
Access to Advanced Health Institute was founded in 1993. It employs 51 to 100 people.
Where is Access to Advanced Health Institute based?
Access to Advanced Health Institute is headquartered in Seattle, United States, in the North America region.
Who are Access to Advanced Health Institute's main competitors?
Direct peers on record are International Vaccine Institute, Sabin Vaccine Institute, PATH, Texas Children's Hospital Center for Vaccine Development (Baylor) and Hilleman Laboratories. Emerging players are Novavax and Gennova Biopharmaceuticals. Broad incumbents are CureVac and Moderna. Coalition for Epidemic Preparedness Innovations (CEPI) is listed as an others.
Does Access to Advanced Health Institute have an API?
No public API is recorded for Access to Advanced Health Institute.
What industry is Access to Advanced Health Institute in?
Access to Advanced Health Institute's product category is Vaccine Research and Development. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 2836.